Third Harmonic Bio (THRD) shares slumped 25% in recent Tuesday trading after the company announced a 50% workforce cut, a strategic review, including potential transactions or business combinations, and a halt in all research unrelated to its THB335 drug candidate for chronic spontaneous urticaria.
THB335 phase 1 data support advancement into a phase 2 clinical trial, the company said Tuesday in a statement. Full results will be presented at a medical conference in March.
The phase 2 trial is expected to start by mid-2025.
Third Harmonic had $285 million in cash and cash equivalents as of Dec. 31.
Price: 3.51, Change: -1.15, Percent Change: -24.62
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.